As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.
Australian Institute for Bioengineering and Nanotechnology researchers have scored crucial funding wins as they push to create the next generation of medicines and treatments.
Join us at our event Science: It’s good business for a conversation about how UQ can enable your success through next generation products and your future workforce.
Needle-free technology, originally developed at the AIBN, has been used to administer a COVID-19 vaccine candidate to successfully protect mice, demonstrating the potential of non-invasive delivery.
Faster-charging and more sustainable batteries with a life up to three times greater than lithium ion are being built with technology developed at AIBN.
A startup company developing technology based on University of Queensland (UQ) research has announced it will partner with the US Government to test its needle-free vaccine delivery technology.